GH Research PLC (NASDAQ:GHRS - Get Free Report)'s share price traded down 4% during mid-day trading on Thursday . The stock traded as low as $11.91 and last traded at $12.07. 58,063 shares traded hands during mid-day trading, a decline of 68% from the average session volume of 181,362 shares. The stock had previously closed at $12.57.
Analyst Ratings Changes
Several research analysts have recently issued reports on the stock. Stifel Nicolaus increased their price objective on shares of GH Research from $18.00 to $32.00 and gave the company a "buy" rating in a report on Thursday, February 27th. Guggenheim decreased their price objective on shares of GH Research from $32.00 to $29.00 and set a "buy" rating for the company in a report on Friday, May 9th. Cantor Fitzgerald upgraded shares of GH Research to a "strong-buy" rating in a report on Tuesday, May 13th. Wall Street Zen cut shares of GH Research from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd. Finally, HC Wainwright reiterated a "buy" rating and issued a $40.00 price objective on shares of GH Research in a report on Friday, May 9th. One analyst has rated the stock with a sell rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $30.43.
Read Our Latest Report on GH Research
GH Research Stock Down 0.8%
The firm has a market capitalization of $623.30 million, a price-to-earnings ratio of -15.16 and a beta of 0.86. The firm's 50 day moving average is $10.31 and its 200 day moving average is $10.15.
GH Research (NASDAQ:GHRS - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.61) by $0.42. On average, sell-side analysts predict that GH Research PLC will post -0.8 earnings per share for the current year.
Institutional Investors Weigh In On GH Research
Hedge funds have recently made changes to their positions in the company. BNP Paribas Financial Markets purchased a new stake in shares of GH Research in the 4th quarter valued at approximately $44,000. Palumbo Wealth Management LLC purchased a new stake in shares of GH Research in the 1st quarter valued at approximately $142,000. XTX Topco Ltd purchased a new stake in shares of GH Research in the 1st quarter valued at approximately $169,000. Two Sigma Investments LP purchased a new stake in shares of GH Research in the 4th quarter valued at approximately $117,000. Finally, Millennium Management LLC purchased a new stake in shares of GH Research in the 4th quarter valued at approximately $145,000. Hedge funds and other institutional investors own 56.90% of the company's stock.
About GH Research
(
Get Free Report)
GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).
Further Reading
Before you consider GH Research, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GH Research wasn't on the list.
While GH Research currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
